Home › Triple-Negative Breast Cancer › Texas › El Paso
Triple-Negative Breast Cancer clinical trials in El Paso, TX
3 studies for Triple-Negative Breast Cancer are looking for participants at sites in and around El Paso (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RecruitingPhase 3
- Texas Oncology - West Texas ( Site 8004), El Paso
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RecruitingPhase 3
- Texas Oncology, El Paso
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RecruitingPhase 2/3
- Texas Oncology - West Texas, El Paso
Triple-Negative Breast Cancer trials in other cities
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Atlanta, GA20 studies
- Arlington, VA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
Other studies in El Paso
- Obesity10 studies
- Overweight8 studies
- Heart Failure7 studies
- Non-Small Cell Lung Cancer6 studies
- Breast Cancer6 studies
- COPD5 studies
- Metastatic Cancer5 studies
- Burkitt Lymphoma4 studies
- Lung Cancer4 studies
- Asthma4 studies
- Cancer (all types)4 studies
- Idiopathic Pulmonary Fibrosis4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.